Homozygous familial hypercholesterolemia and its management

Area of Science:

• Genetics
• Cardiology
• Metabolic Disorders

Background:

• Familial hypercholesterolemia (FH) is an inherited disorder characterized by mutations in the low-density lipoprotein (LDL) receptor gene.
• Homozygous FH involves mutations in both LDL receptor genes, leading to severely elevated LDL cholesterol levels.
• Associated features include reduced high-density lipoprotein cholesterol, elevated lipoprotein(a), and early onset of xanthomata.

Purpose of the Study:

• To summarize the genetic basis, clinical presentation, diagnosis, and management of homozygous familial hypercholesterolemia.
• To highlight the accelerated atherosclerosis and cardiovascular complications associated with this condition.
• To review current and emerging therapeutic strategies for managing severe hyperlipidemia in FH.

Main Methods:

• Review of literature on familial hypercholesterolemia, focusing on genetic mutations, pathophysiology, and clinical outcomes.
• Analysis of diagnostic methods including genetic testing and LDL receptor function studies.
• Evaluation of treatment modalities such as lipid-lowering medications, apheresis, and organ transplantation.

Main Results:

• Mutations in the LDL receptor gene are the primary cause of FH, with homozygous forms exhibiting extreme hypercholesterolemia.
• Patients present with xanthomata in childhood and develop severe aortic and coronary atherosclerosis early in life.
• Diagnosis is confirmed via genetic analysis or cellular studies of LDL receptor function.

Conclusions:

• Homozygous FH necessitates aggressive management including plasmapheresis, high-dose statins, and ezetimibe to mitigate cardiovascular risk.
• Liver transplantation offers a potential cure by addressing the metabolic defect but requires careful consideration of immunosuppression and potential complications.
• While gene therapy is not yet feasible, ongoing research holds promise for future treatment options.